

The Use of Health Information Technologies:

New Opportunities for Research and Improvement in the Safety and Effectiveness of Prescription Drugs


The Rx Road



The Rx Road



The Rx Road



The pharmacist has trouble reading the rx and dispenses 400 mg of Dilantin—200 mg per day was prescribed

A MARK THE A	
the second second	
Pour	
Adress	\times
B Coma	din Twilletter
Jutal 80 !	prest for
annint 1	o los Asom
pretRom	~ ~ 5, J # 60
warshie !	n 10/ do #20m
upo jo fu	July 1 m 65 il X/W
arkins	seled in Hour
[second	





Mme Blanc is hospitalized for her hip fracture for surgery and rehab

Mme Blanc is dizzy from too high a dose of Dilantin, falls down her steps, and fractures her hip

The Expected Benefits of Health Information Technologies

➢Safety

Reduce Prescribing + Transcription Errors

Improve Follow-up Monitoring

Ouality
 Improve Appropriateness
 Improve Adherence

Drug Costs

Improve Cost-Effective Prescribing

Post-Market Surveillance

Provide New Tools for Pharmacosurveillance



Safety



"I can tell this prescription is a phony. The doctor's signature is legible."

Computerizing Prescribing

Reduce Potential Errors By Providing Menus for Dose Selection

	New Prescripti	ion		Print Blan	nk Rx	
	Add New Drug	g: prinivil				
	The new presci	rip [™] PRINIVIL TABLET 2	2.5MG			
		™PRINIVIL TABLET 5	iMG			
		™PRINIVIL TABLET 1	0MG			
	-	™PRINIVIL TABLET 2	20MG			
Prescript	lion					Print Blank
I New Drug ect: <u>All No</u>	n one 🔚 <u>Save</u> 🔚	Save and Print 🥥 Delete	P2003-04.163/1034-011/52			1
I New Drug ect: <u>All No</u>	r	Save and Print October Posology	Quantity/Duration	Indication(s)		1
I New Drug ect: All No	r one 🔄 <u>Save</u> 🔄 Drug PRINIVIL	Market Mark	P2003-04.163/1034-011/52	A CONTRACTOR OF A CONTRACT	• 0	1
I New Drug ect: All No] Tuy T	PRINIVIL ABLET 5MG	Posology	Quantity/Duration		• 0	1
I New Drug ect: All No] Tuy T	prince Save In Save	Posology	Quantity/Duration	Essential (primary) hypertension Heart failure	• 0	Stop/Change Reason
I New Drug ect: All No] Tuy T	prince Save In Save	Posology 1.00 V TABLET 🖉 qAM V	Quantity/Duration 30 Day(s) 💌 12 Refills 👻	Essential (primary) hypertension	0	

Computerizing Prescribing

Handwritten Vs. Computer-Generated Prescriptions


Pour Adress B connadin S Well att 34m Johd of 80 5, 0 # 65 M annint 10,000 #30m Met Romin DN 5, 1460 Arandia M 10/ du #20m anon seled in Horn REPETATUR NR

MOXX		il, 23 février, 2009
	Dr. Training User 6 M.D. Test Establishment for test patients 1140 Pine West, Montreal, Guebeo, H3A-1A	3
	PETRELLI, ANTOINE (PETA47060836, Age: 6	51]
	PRESCRIPTION	
1/4-	CENTRUM SELECT COMP.CROQ. #30x30 Jour(s) 1 COMP.CROQ. die Note:	Rép:8
2/4-	COUMADIN SMG COMPRIME #30x30 Jour(s) 1 COMPRIME die Note:	Rép:8
3/4-	HYDROCHLOROTHIAZIDE 12.5MG COMPRIME #30x30 Jour(s) 1 COMPRIME qAM avec le(s) repas Note:	Rép:6
4/4-	METFORMIN 500MG COMPRIME #90x30 Jour(s) 1 COMPRIME tid avec le(s) repas Note:	Répi
	ng User 5 se: 55550	Pg. 1

Computerizing Prescribing

Typed Prescriptions Reduce Prescribing & Transcription Errors

Ammenworth et.al. Vol 15, No 5, JAMIA, 2008 (figure 6)



Computerized Decision Support

Providing Automated Alerts for Prescribing Problems

Suppress Alerts

Type \$	Drug(s)	Level \$	Suppress	
Diabetes: use with caution, may mask some symptoms	METOPROLOL 24H-TABLET 200MG	┩ (Moderate)	v	
ojinpromo			 Suppress for this patient only 	
			O Suppress for all patients	
antagonism	METOPROLOL 24H-TABLET 200MG	┩ (Serious)	· · · · · · · · · · · · · · · · · · ·	
	 MVENTOLIN HFA METERED INH. 100MCG 		 Suppress for this patient only 	
			O Suppress for all patients	

Computerized Decision Support

On-Demand vs. Automated Drug Alerts

Tamblyn et al, JAMIA, July/August, 2008

% Seen and Revised in 3,449 Patients						
Characteristic	On Demand Alerts	Automated Alerts				
Number of Patients	1,550	1,899				
Number of Alerts	4,445	6,506				
% Seen	0.9%	10.3%				
% Revised that were Seen	75.6%	12.1%				



However Most Drug Alerts from Commercial Systems are Ignored!

Weingart et.al. Archives Int Med. 2003

Physicians over-ride 49% to 96% of alerts for drug-allergy, drug-drug and drug-disease contraindications

Experienced physicians more likely to over-ride alerts than trainees

Incorrect data explains most allergy and pregnancy alerts

Benefit greater than risk" reason for most over-rides

Incorporating Epidemiological Science into Risk-Benefit Assessment

UKPDS Risk Engine

OXFORD DIABETES TRIALS UNIT The Oxford Centre for Diabetes, Endocrinology and Metabolism


Home page

Background

Risk calculators based on equations from the Framingham Heart Study tend to underestimate risks for people with diabetes as this study included relatively few diabetic subjects. The UKPDS Risk Engine is a type 2 diabetes specific risk calculator based on 53,000 patients years of data from the UK Prospective Diabetes Study, which also provides an approximate 'margin of error' for each estimate.

000	UK	PDS Risk Eng	ine v2.0		
Input					
Age Now :	62	years	HbA1c :	8.3	%
Duration of Diabetes :	11	years	Systolic BP :	145	mmHg
Sex :	Male	Female	Total Cholesterol :	5.8	mmol/I
Atrial Fibrillation :	No	○ Yes	HDL Cholesterol :	1.1	mmol/l
Ethnicity :	White		•		
Smoking :	Non-S	moker	•	0	tions >
Output				Cop	
10	year risl	k 0 15	30		100
CHD :	33.3%				
Fatal CHD :	24.4%	H	1		
Stroke :	11.6%				
Fatal Stroke :	1.8%	l I			
	Adjus	ted for regress	sion dilution		
Details		Сору	\square	Print	
Details		Help	\supset	Exit	

Designing New Smart Alerts that Provide Person-Specific Risk Assessment




Integrating Computerized Prescribing with Drug Dispensing Information


Coming Soon to Canada!



Multiple Prescribing Physicians Increase the Risk of Inappropriate Prescriptions

Tamblyn et. al., CMAJ, 1993





Improving Safety

Retrieving a Complete Drug Profile from an Integrated Drug Management System


Sele	ct: A	II None 💿 Represcribe 🥌 Stop 🥅 Prescription History	IIII Lege	nd 🗎 Print		
		Drug	2008-09	2008-10	2008-11	2008-12
		CENTRUM SELECT				
		COUMADIN 5MG				
		GEN METFORMIN 500MG				
		ER Visits / Hospitalizations:				
		Patient \$ / RAMQ \$:	7 / 18	0/0	0/0	
		Legend	×			
		Prescribed by you with MOXXI-NG but yet dispensed	not			
		Prescribed by you and dispensed				
		Prescribed by another physician (dispensed)				
		(Darker colours represent a drug overla	ip)			
		ER Visits / Hospitalizations				

- Today's date
- Prescription Stopped
- 💈 Change of dose
- Drug associated with an alert

Physicians Using the Integrated Drug Profiler

For Patients with Multiple Drugs and Low Income

Yuko Kawasami et.al. International Journal of Medical Informatics, 2007



Total Number of Prescriptions (Jan- Nov 2003)

Evidence-Based Treatment




Computerized Decision Support

To Improve Quality of Care and Patient Outcomes

Systematic Review; Garg et.al. JAMA, March 9, 2005

Improvement in Quality of Care	Number of Trials	Success Rate
Diagnostic Decision-Making	10	40%
Patient Care Reminder Systems	21	76%
Disease Management Decision-Support	37	62%
Drug Dosing	29	66%
Improvement in Patient Outcomes	Number of Trials	Success Rate
All systems	52	13%

Health Information Technologies that Improve Outcomes Target High-Risk Populations



Daily Surveillance of ER Visits and Rescue Medication to Assess Asthma Control


MOXXI-NG - Patient Profile- LISA SIMPSON (3 https://moxxi.irisquebec.ca/moxxi/views/pati My Patients My Practice Monogra Summary Problems Allergies M Print Problems Allergies M	edications Patient Monitoring Z	Provincial Data Rola El Halabieh
General Information NAM: SIML80031416 First Name: LISA Age: 31 Birth Date: 1980-03-14 VYYYAMADD Weight: Gender: Female Email: iphigenia.symeonidis@mcgill Telephone(s): Residence: (514) 555-555 Cell: (514) 555-555	5	
Edit Close	Kemove consent	

Computerized Decision Support for Evidence-Based Asthma Management

198	the second s				
	patient's asthma appears to be OUT OF CONTROL t visit: Not Available 🛛 View Asthma History 🛛 🍱 MA	P Action Plan not available	🖾 Education Resources 🦓 Treatment Guidelines		
	a Profile		Suggested Treatment		
1.	Please validate drugs and posologies		5. Select Recommendation		
1	Drug	Posology	Recommendation		
	WVENTOLIN HFA 100MCG	1-2 INH 🔻	ADD LABA SEREVENT DISKUS 50 1 INH BID.		
	TIFLOVENT DISKUS 100MCG	1 INH BID +	STOP FLOVENT DISKUS & START ADVAIR DISKUS 100 1 INH BID.		
4			INCREASE FLOVENT DISKUS DOSE & CHANGE STRENGTH TO 250 1 INH BID		
			add LTN SINGULAIR 10MG PO QD.		
2.	Respiratory-related ER Visits & Faba Medication Usage		Determining Drug: (FLOVENT DISKUS 100MCG 1 INH BID)		
	Respiratory-related ER visits in the past 3 months; 1 visit(s)				
	Dispensed FABA medications in the past 3 months: dose >= 2	50	6. Prescribe Fast Acting B Agonist (FABA) if needed		
3.	In the last week, the patient has:		SALBUTAMOL MDI 100 1-2 INH AS NEEDED		
1	Trouble breathing on 4 or more days		TERBUTALINE 500 1 INH AS NEEDED		
	Use of rescue inhaler 4 or more times		7. Apply Changes		
	Awakened due to asthma		O Proceed with Changes		
+	Unable to carry out usual activities		Droceed with Changes And Print		
	Missed school or work because of asthma				
1	Had an urgent medical visit for asthma				
4.	Update				
		O Update Suggested Treatment			


Computerized Decision Support for Evidence-Based Asthma Management

Tamblyn, Ernst, Winslade: CIHR RCT## NCT00170248



Providing Patients with Self-Management Tools within a Personal Health Record

Dr. Sara Ahmed, McGill University: CIHR Research in Progress



Providing Patients with Self-Management Tools within a Personal Health Record

Dr. Sara Ahmed, McGill University: CIHR Research in Progress

**************************************	sited 🚽 MOXXI-NG 🚽 Work 🕌 Java 🖕 ssues - M 🕅 0000745: Make 🕅 000	0884: Make 🕅 0001047: Adjus 🥅 0000969: Pop-u 🥅 0001172: asthm 🥅		sthm × ÷ =
	← Back to Patient List	Lisa Simpson SIML80031416	🚔 Print 🥁 Compose Mail 📝 Add Note	
		General Medical Action Plan / Medication List My Asthma	Target Patient Mail Notes Activity Log	
	Patient Summary	Health Care Team Information Patient Generated Infor	rmation	
	OOC Status: OOC since 2010-05-17	Basic Information		
	Current Alerts: • Create patient AP • Review patient AP • Change to control med usage • AP not started • Patient not logging in	First Name: Lisa Special needs: None Address: No address entered	Gender: Female 0 Kilogram(s) Height: 179.00 Centimetre(s)	
	Next Contact: None recorded	Contact Information Email Address: jonathan.richard@mcgill.ca Tele	ephone(s): No telephone numbers entered	
	Patient Meds: • Flovent Diskus Powder Inh. 100mcg • Ventolin Hfa Metered Inh. 100mcg • Ventolin Hfa Metered Inh. 100mcg Setting/Physician: Clinique médicale de McGill Dr. Rola El Halabieh Start Date: 2007-12-07 (133 weeks) Preferred language:			E
	French Last updated: 2010-05-24			

Treatment Adherence


© Original Artist Reproduction rights obtainable from www.CartoonStock.com



"Mr. Fillchock, it's time for your 8 p.m. pills. Please choose the pills that match these shapes, sizes and colors..."

Medication Non-adherence Reduces the Benefits of Treatment for Stroke and Myocardial Infarction Prevention

Tamblyn et. al. Archives of Internal Medicine, 2010




Treatment Adherence

LEVJ24121711 Age: 83 🖉 Refresh 🚭	MOXXI
LAST NAME LEVASSEUR	Back
FIRST NAME JEAN	JUL. 24, 2008 - AUG. 23, 2008 Click on alert message for more details
PROBLEMS ALLERGY DRUG PROFILE ALERTS ASTHMA Incodentities FEB MAR APR MAY JUN JUL COSOPT Image: Cost of the second	TRAVATAN (TRAVOPROST) 0.004% EYE DROPS #2.50 x30D NR PATIENT/RAMQ(\$): \$ 0.00/36.48 JUN. 7, 2008 - JUL. 7, 2008 APR. 25, 2008 - MAY. 25, 2008 MAR. 13, 2008 - APR. 12, 2008 JAN. 25, 2008 - FEB. 24, 2008
TRAVATAN PATIENT/RAMQ(\$): \$8/362 \$0/367 75/349 \$3/209 \$6/229 75/266 HOSPITALISATION Prescribed by you with MOXXI but not yet dispensed Prescribed by you and dispensed Prescribed by another physician (dispensed) Sample (Darker colors represent a drug overlap) Today's date Prescription Stopped Change of dose Med Drug associated with an alert	Alert Monography
Print Print	


Increasing the Detection and Response to Adherence Problems with Cardiovascular Medication in Primary Care through Computerized Drug Management Systems: A Randomized Controlled Trial

Tamblyn et. al., Med Decis Making 2010;30:176-188



Reasons for stopping/changing cardiovascular medications


Tamblyn et.al. Medical Decision-Making, 2009



Opportunities to Prevent or Ameliorate Adverse Drug Events

Ghandi et al. NEJM, April 2003

N = 661




<u>Ameliorable ADE's (51)</u> •Failure of physician to respond to medication-related symptoms - 32 (63%) •Failure of patient to inform

physician of symptoms - 19 (37%)

<u>Preventable ADE's (20)</u>
Selection of wrong drug - 9 (45%)
Wrong dosage - 2 (10%)
Wrong frequency of use - 2 (10%)

•Preventable by advanced systems of medication ordering - 7 (35%)


IVRS: Monitoring the Early Effects of Medication




Feasibility and Acceptability of IVRS

n=496

Was the calling system easy to use?




If this type of calling system were provided by your doctor, would you continue to use it?



Detection of Adverse Drug Events and Prescription Issues Using IVRS

Forster et. al CIHR grant #2456 2010



Practice Monitoring Tools: Alerting Physicians about New Problems with Medications


atient Monitoring -	- Important new info	ormation	wailable! [Cli	ick this bar	to minimize]					**
The following pa	atient(s) have report	ted advers	e drug reaction	is with their i	recently prescribed drug	ı(s):				~
First Name 🗢	Last Name 🔹	Age ¢	Gender +	Drugs	Reaction and Severit	ty ¢			Date Reported 🔹	
NICOLAS	SANTERRE	43	Male	™PAXIL	trembling & shaking increase sleep or di	g of fingers & h rowsiness (MIL	ands (MODERATE D))	September 14, 2009	
arch patients by: N			st name only, fi Q <u>Search</u> 🥥		name (in that order) or l		ne separated by a	ı comma.	Reset My Trainin	Tatients
atient Searc arch patients by: N chute							ne separated by a	a comma.	Reset My Trainin	
arch patients by: N				Clear	O Create a New Patier		ne separated by a	a comma. File No ♦	Reset My Trainin	

Practice Monitoring Tools: Alerting Physicians about New Problems with Medications

		ws/patient/sectionu	08.seam?cid=155						
nmary	Problems	Allergies	Medications	Patient Monitorir	ng Alerts Asthma	Notes		NICOLAS S	
lood Pres	ssure M	edication Monitor	ing						
Adverse Drug Reactions									
ource +	Date Repo	rted + C	rug	Indicat	ion	Adverse F	eaction		
	September	r 14, 2009 T	MPAXIL TABLET 2	OMG Obses	sive-compulsive disorder	trembling	& shaking of fingers sleep or drowsiness	& hands (MODERATE) (MILD)):
dverse F	Reaction Det	tails - Medicatior	Monitoring Tele	phone Interview					
™PAXIĽ Interviev	w Date: <mark>Se</mark> p	2009-08-19 etember 14, 2009		ned amy exent incl			lition abnormal char		<u>e Details</u>
	-	t, accidents, falls			uding new symptoms, char	ige in their con		iges in labor acory tes	as, ranure
Yes - ma Has the No	peutic effect ains qui trem patient been	t, accidents, falls nblent n in hospital or en	etc?	ent for any reasor	uding new symptoms, char	ige in their con		iges in labor actry (es	as, ianu e
Yes - ma Has the I No Has the I Symptor	peutic effect ains qui trem patient been patient ident m	t, accidents, falls hblent h in hospital or en tified any symptor	etc? nergency departm ns since starting Severity	ent for any reasor the medication? Duration	n after starting this drug?	ige in their con		iges in labor actry (es	ιτ ο, ταπατ ε
Yes - ma Has the No Has the Symptor tremblir	peutic effect ains qui trem patient been patient ident m ng & shaking	t, accidents, falls hblent h in hospital or en tified any symptor g of fingers & ha	etc? nergency departm ns since starting Severity nds MODERATE	the medication? Duration less than 2 wee	n after starting this drug? ks	ige in their con		iges in landi acti y tes	ιτ ο, ταπάτ ε
Yes - ma Has the No Has the Symptor tremblin increase Has the	peutic effect ains qui trem patient been patient ident m ng & shaking e sleep or dr	t, accidents, falls nblent in in hospital or en tified any symptor g of fingers & ha rowsiness	etc? nergency departm ns since starting Severity	the medication? Duration less than 2 wee less than 2 wee	n after starting this drug? ks	ige in their con		iges in laworatory tes	ις, ταπατ ε
Yes - ma Has the No Has the Symptor tremblir increase Has the none	peutic effect ains qui trem patient been patient ident m ng & shaking e sleep or dr patient ment	t, accidents, falls nblent n in hospital or en tified any symptor g of fingers & ha rowsiness tioned these sym	nergency departm ns since starting Severity MILD ptoms to their phy	the medication? Duration less than 2 wee less than 2 wee	n after starting this drug? ks	ige in their con		iges in land active (es	ις, ταπατε
Yes - ma Has the No Has the Symptor tremblir increase Has the none Has the	peutic effect ains qui trem patient been patient ident m ng & shaking e sleep or dr patient ment patient stop	t, accidents, falls nblent n in hospital or en tified any symptor g of fingers & ha rowsiness tioned these sym	nergency departm ns since starting Severity MILD ptoms to their phy medication?	the medication? Duration less than 2 wee less than 2 wee	n after starting this drug? ks	ige in their con		iges in land active (es	ις, ταπατε
Yes - ma Has the No Has the Symptor tremblir increase Has the none	peutic effect ains qui trem patient been patient ident m ng & shaking e sleep or dr patient ment patient stop Stopped?	t, accidents, falls nblent in hospital or en tified any symptor g of fingers & ha rowsiness tioned these sym ped taking their Date Stopped F	etc? hergency departm ns since starting Severity nds MODERATE MILD ptoms to their phy medication? Reason	the medication? Duration less than 2 wee less than 2 wee ysician?	n after starting this drug? ks	ige in their con		iges in land active (es	ις, ταπατε
Yes - ma Has the I No Has the I Symptor tremblin increase Has the I Drug TYPAXIL Have one	peutic effect ains qui trem patient been patient ident m ng & shaking e sleep or dr patient ment patient stop Stopped?	t, accidents, falls herefore the set of the	etc? hergency departm ns since starting Severity nds MODERATE MILD ptoms to their phy medication? Reason	the medication? Duration less than 2 wee less than 2 wee ysician?	n after starting this drug? ks	ige in their con		iges in land active (es	ις, ταπατε

New Opportunities to Enhance Cost-Effectiveness

Drug Costs in Canada, 2004: \$130 Billion




Drug Costs and Adverse Effects are the Most Common Causes of Non-Adherence

atient Management 🔤 Messaging 🚴 My Profile 🥃 Monograj	hs 🗾 Logout	<u>Français</u>
nmary Problems Allergies Medications Alerts	Asthma	
Print 🚔 Print Full Record		
neral Information	0 New Problem(s)	
IAM SIMH58111112 Age 49 irst Name HOMER File No 1234 .ast Name SIMPSON Gender Male		
Edit Kemove consent		
Patient Out-of-Pocket Savings Recommender		
Patient Out-Of-Pocket Savings (OoPS) opportunity for anti- hypertensive therapy is shown below:		
Current annual Out-Of-Pocket Expense	867.00	
Annual Out-Of-Pocket Expense with a diuretic	671.00	
Total annual Out-Of-Pocket Savings	196.00	
Q Optimize Patient OoPS		
<u>256</u>		


moxxi.irisquebec.ca 🚨 🕘 🍕

Terminé

Drug Costs and Adverse Effects are the Most Common Causes of Non-Adherence




Surveillance




Using electronic prescribing to collect drug indication and treatment outcome (MOXXI)

lew Prescription												
Ad	ld New	Drug:						🖨 Pri	int Blank Rx			
Se	Select: <u>All</u> <u>None</u> 🔚 <u>Save</u> and Print 🤤 <u>Delete</u>											
		Drug	Poso	logy	Quantity/Duration		Indication(s)	Stop/Change Reason				
]	GABAPENTIN 100MG CAPSULE Sample:		PSULE 🖉	30 Day(s) 6 Refills ✓ Otty 90.00	~	Aggressive/Antisocial Behavior Bipolar affective disorder Diabetic Neuropathy Epilepsy Essential Tremor					
You selected to stop the following drug(s). Please select a stop reason for each of them.												
	GAE	Drug APENTIN 100MG	Posology 1.00 CAPSULE tid		ity/Duration) Day(s), 6 refills		Reason	v				
		ave 🔀 Cancel				Safe Safe Erro Effe Effe Exte Exte Adh	ety: Adverse drug reaction ety: Allergic response ety: Drug interaction or: Prescribing or: Dispensing ectiveness: Ineffective treatment ectiveness: No longer necessary ernal factor: New evidence ernal factor: New evidence ernal factor: Discontinued by another physician ernal factor: Patient request herence: Simplifying treatment herence: Substitution of less expensive drug					

Can you guess the treatment indication for these antidepressants from the drug?




Monitoring Off-Label Use




Why are Drugs Discontinued?


Reasons for Drug Discontinuation Orders written for 857 of 3889 MOXXI Patients Seen Between Nov, 2005- Jan, 2006



Comparative effectiveness of anti-depressants




Which statin do you avoid (or prescribe)?



The Future?? Real-Time Monitoring and Feedback from Analysis of International Computerized Prescribing Systems

Tamblyn, Abrahamowicz, Wolfson, Bates, Dixon: CIHR International Pharmacosurveillance






Thank you!


robyn.tamblyn@mcgill.ca

Medication Reconciliation Made Easy

Agrawal et.al. Joint Commission Journal on Quality and Patient Safety, Vol 35, No 2, 2009



Unintended Discrepancies in Community Medications Charted for 838 Patients seen in the MUHC Emergency Department



Legibility of Drugs in Emergency Department Charts for 838 Patients Seen in the MUHC

